JAK2 V617F Mouse Gene Sequencing Analysis: Comprehensive Genotyping Services for Myeloproliferative

JAK2 V617F mouse gene sequencing analysis is a specialized molecular testing service designed to detect and quantify the JAK2 V617F point mutation in genetically engineered mouse models. This analysis enables researchers to confirm genotypes, monitor mutant allele burden, and advance studies of myeloproliferative neoplasms (MPNs) with high sensitivity and accuracy. Our comprehensive sequencing workflow supports both qualitative genotyping and quantitative allele burden assessment for preclinical research applications.

Technical Overview

The JAK2 V617F mutation is a somatic gain-of-function point mutation in the Janus kinase 2 (JAK2) gene, resulting from a G to T substitution at nucleotide 1849 (c.1849G>T). This mutation converts valine to phenylalanine at position 617 of the JAK2 protein, located within the pseudokinase (JH2) domain. The substitution disrupts the autoinhibitory interaction between the JH2 domain and the kinase (JH1) domain, leading to constitutive activation of JAK2 signaling and downstream JAK-STAT pathway hyperactivation.

In humans, the JAK2 V617F mutation is the hallmark genetic lesion of Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), present in approximately 95% of polycythemia vera cases and 50–60% of essential thrombocythemia and primary myelofibrosis cases. To model these diseases in vivo, researchers have developed multiple JAK2 V617F knock-in and transgenic mouse models, including conditional Cre-LoxP-based models (such as Jak2^V617F/flox crossed with Mx1-Cre, Vav1-Cre, or Pf4-Cre lines), humanized JAK2 V617F transgenic lines, and hematopoietic transplantation-based models.

Accurate genotyping and mutation analysis of these mouse models are essential for colony management, experimental reproducibility, and disease monitoring. JAK2 V617F mouse gene sequencing analysis provides reliable detection of the mutant allele in genomic DNA extracted from various biological samples, along with quantitative measurement of mutant allele burden in heterozygous or homozygous mutant animals.

Testing Samples

Tail Tissue Biopsies

Tail tip biopsies (1–2 mm) collected from pups at 10–21 days of age are the most common sample type for routine genotyping. Tail snips provide sufficient genomic DNA for PCR amplification and sequencing analysis, and the procedure is minimally invasive when performed according to approved animal welfare protocols.

Ear Punch Biopsies

Ear punch samples collected during routine identification ear-notching offer a dual-purpose approach, combining animal identification with genotyping. This sampling method reduces the number of procedures performed on each animal and provides high-quality genomic DNA suitable for JAK2 V617F detection.

Peripheral Blood and Bone Marrow

For studies requiring assessment of mutant allele burden in hematopoietic cells, peripheral blood collected via submandibular or tail vein puncture, as well as bone marrow aspirates or flushed femurs and tibias, can be submitted. These samples are particularly valuable for longitudinal monitoring of disease progression in MPN mouse models.

Splenic and Other Organ Tissues

Spleen, liver, and other affected tissues harvested at necropsy may be analyzed to evaluate extramedullary hematopoiesis and mutation distribution across disease-affected organs. Fresh or frozen tissue samples are acceptable, and fixed tissue can be processed following deparaffinization when necessary.

Sorted Cell Populations

FACS-sorted hematopoietic stem cells, progenitor cells, or lineage-specific populations can be submitted for clonal analysis. Low-input DNA extraction protocols are available for samples with limited cell numbers, supporting studies of mutation distribution across the hematopoietic hierarchy.

Testing Items

Our JAK2 V617F mouse gene sequencing analysis portfolio covers the full spectrum of genotyping and mutation assessment needs:

• JAK2 V617F point mutation detection (c.1849G>T confirmation) in mouse genomic DNA
• Qualitative genotyping of wild-type, heterozygous (Jak2^+/V617F), and homozygous (Jak2^V617F/V617F) animals
• Conditional allele verification, including floxed allele confirmation and Cre-mediated recombination detection in conditional knock-in models
• Quantitative mutant allele burden measurement (variant allele fraction determination)
• Sanger sequencing of full-length JAK2 exon 12 and adjacent intronic regions for additional variant screening
• Verification of transgene integration and copy number assessment for transgenic JAK2 V617F lines
• Zygosity determination to support breeding colony management and experimental design
• Mixed chimerism and post-transplantation engraftment analysis in bone marrow transplantation studies

Testing Methods

Polymerase Chain Reaction (PCR) Amplification

Genomic DNA is extracted from submitted samples using optimized purification protocols that ensure high DNA yield and purity. PCR primers are designed to flank the JAK2 exon 12 region containing the V617F locus, generating amplicons of appropriate length for downstream analysis. Primer design accounts for the specific mouse strain and knock-in construct architecture to ensure specific amplification of the target allele.

Sanger Sequencing

Sanger sequencing remains the gold standard for definitive JAK2 V617F mutation confirmation. Bidirectional sequencing of PCR amplicons provides clear chromatographic evidence of the c.1849G>T substitution. Heterozygous samples display overlapping G and T peaks at the mutation position, while homozygous samples show a complete T peak. This method reliably detects mutant allele fractions down to approximately 15–20%.

Allele-Specific PCR (ASO-PCR)

Allele-specific oligonucleotide PCR employs mutation-specific primers that selectively amplify either the wild-type or V617F mutant allele. Combined with internal control amplification, this method enables rapid genotyping with enhanced sensitivity compared to conventional PCR and Sanger sequencing, achieving detection limits of approximately 1% variant allele fraction.

Quantitative Real-Time PCR (qPCR)

TaqMan-based qPCR assays using allele-specific fluorescent probes enable precise quantification of mutant allele burden. By comparing amplification of mutant and wild-type allele signals against standard curves generated from calibrated reference DNA mixtures, this approach accurately determines variant allele fractions across a dynamic range suitable for disease monitoring.

Droplet Digital PCR (ddPCR)

For applications requiring ultrasensitive detection, ddPCR partitions reactions into thousands of individual droplets, enabling absolute quantification of mutant and wild-type alleles without the need for standard curves. ddPCR achieves detection sensitivities of 0.1% variant allele fraction or lower, making it ideal for minimal residual disease assessment and low-level chimerism studies.

Next-Generation Sequencing (NGS)

Targeted amplicon-based NGS offers deep sequencing coverage of the JAK2 locus, combining mutation confirmation with quantitative allele burden measurement at detection sensitivities below 0.5%. NGS workflows can be multiplexed to include additional MPN-associated genes (such as Calr, Mpl, and TET2) for comprehensive mutational profiling in mouse disease models.

Applications

JAK2 V617F mouse gene sequencing analysis supports a wide range of research and preclinical applications:

• Genotype confirmation for JAK2 V617F knock-in and transgenic mouse colonies prior to experimental enrollment
• Phenotypic studies of myeloproliferative neoplasms, including polycythemia vera-like disease, essential thrombocythemia, and myelofibrosis modeling
• Longitudinal monitoring of mutant allele burden during disease initiation, progression, and therapeutic intervention
• Preclinical evaluation of JAK inhibitors (such as ruxolitinib, fedratinib, and pacritinib) and emerging targeted therapies
• Bone marrow transplantation studies assessing disease initiation capacity and clonal dynamics of mutant hematopoietic stem cells
• Conditional knock-in model studies examining tissue-specific and lineage-specific mutation effects via Cre-LoxP recombination verification
• Drug resistance mechanism studies and combination therapy optimization in MPN models
• Comparative oncology research investigating cooperation between JAK2 V617F and additional mutations in disease evolution

FAQ

What sample types are most suitable for JAK2 V617F genotyping?

Tail snips and ear punches are the recommended sample types for routine genotyping, as they yield ample genomic DNA with minimal invasiveness. Blood, bone marrow, and organ tissues are preferred when assessing allele burden in disease studies. We recommend submitting samples in the provided DNA preservation buffer or on ice for fresh tissue to ensure optimal DNA quality.

How sensitive is the detection of the JAK2 V617F mutation?

Detection sensitivity depends on the method selected. Sanger sequencing reliably detects variant allele fractions of 15–20% or higher, allele-specific PCR and qPCR achieve approximately 1% sensitivity, and ddPCR reaches 0.1% or lower. Our technical team can help select the appropriate platform based on your experimental requirements and expected mutant allele frequencies.

Can the analysis distinguish heterozygous from homozygous JAK2 V617F mice?

Yes. Sanger sequencing chromatograms clearly differentiate heterozygous animals (overlapping G/T peaks) from homozygous mutants (single T peak) and wild-type animals (single G peak). Quantitative methods such as qPCR and ddPCR provide precise variant allele fraction values of approximately 50% for heterozygous and 100% for homozygous animals, confirming zygosity with high confidence.

Is the analysis compatible with conditional Jak2 V617F floxed mouse models?

Absolutely. Our assay panel includes verification of the floxed allele configuration, detection of Cre-mediated recombination events, and confirmation of V617F mutation expression following recombination. This comprehensive approach ensures accurate genotyping throughout the complex breeding schemes required for conditional model maintenance and experimentation.

What is the typical turnaround time for results?

Standard Sanger sequencing-based genotyping results are typically delivered within 3–5 business days of sample receipt. Quantitative ddPCR and NGS analyses require approximately 7–10 business days due to additional bioinformatics processing. Expedited services are available for time-sensitive colony management decisions.

How should samples be stored and shipped?

Tail snips and ear punches may be stored at 4°C for up to one week or frozen at -20°C for longer periods prior to shipping. Blood samples should be collected into EDTA anticoagulant tubes and shipped cold. Fresh tissues should be snap-frozen in liquid nitrogen and shipped on dry ice. Detailed sampling and shipping guidelines are provided with every submission kit.